DHRS11 Antibody

What is DHRS11 and what cellular functions does it perform?

DHRS11 (Dehydrogenase/reductase SDR family member 11) is an NADP+-dependent enzyme belonging to the short-chain dehydrogenases/reductases (SDR) family . It serves multiple enzymatic functions:

• Catalyzes the conversion of 17-keto groups of estrone, 4- and 5-androstenes, and 5-alpha-androstanes into their 17-beta-hydroxyl metabolites

• Converts 3-keto groups of 3-, 3,17- and 3,20-diketosteroids into their 3-hydroxyl metabolites

• Exhibits reductive 3-beta-hydroxysteroid dehydrogenase activity toward 5-beta-androstanes, 5-beta-pregnanes, 4-pregnenes, and bile acids

• May reduce endogenous and exogenous alpha-dicarbonyl compounds and xenobiotic alicyclic ketones

The enzyme plays a significant role in steroid metabolism and potentially in detoxification pathways through its diverse substrate specificity.

What is the tissue expression pattern of DHRS11?

DHRS11 demonstrates a distinct expression pattern across human tissues:

For isoform 1, expression is ubiquitous with the highest levels in the tissues listed above . Isoform 3 shows a more restricted expression pattern, primarily in brain, heart, and skeletal muscle . In non-human species such as rabbit, DHRS11 has been abundantly detected in the brain, heart, kidney, and intestine by RT-PCR .

What validation methods should I use for DHRS11 antibodies?

For comprehensive validation of DHRS11 antibodies, a multi-technique approach is recommended:

• Western Blotting (WB): Verify specificity by confirming a single band at approximately 28.3 kDa, the calculated molecular weight of DHRS11

• Immunohistochemistry (IHC): Use tissues known to express DHRS11 positively (testis, brain, heart) and negatively as controls

• Orthogonal RNAseq validation: Compare antibody staining patterns with RNA expression data to confirm consistency between protein and transcript levels

• Immunofluorescence (IF): Utilize for subcellular localization studies (Atlas Antibodies validates their antibodies using IHC, ICC-IF, and WB)

• Sibling antibody comparison: When possible, compare results with multiple antibodies targeting different epitopes of DHRS11 to ensure consistent staining patterns

What are the recommended dilutions for different applications of DHRS11 antibodies?

Based on multiple commercial antibodies, the following dilutions are recommended:

These ranges represent starting points, and researchers should perform dilution series optimization for their specific experimental conditions and sample types.

How do human and rabbit DHRS11 differ in substrate specificity, and how might this impact cross-species research?

Human and rabbit DHRS11 exhibit significant differences in substrate specificity despite sharing 92% amino acid sequence identity . These differences include:

These differences are attributed to key amino acid variations, particularly at positions 163 (Thr in human vs. Gly in rabbit) and 200 (Val in human vs. Leu in rabbit) . When conducting cross-species research or using antibodies across species, researchers should consider these functional differences as they may affect interpretation of results, particularly in enzyme activity studies. The specific differences in substrate binding regions might also influence epitope accessibility for antibodies targeting these regions.

What experimental controls are essential when using DHRS11 antibodies for analyzing steroid metabolism?

When studying DHRS11's role in steroid metabolism, several critical controls should be implemented:

• Competitive substrate controls: Include experiments with known DHRS11 substrates (estrone, 4-androstenes) to demonstrate enzyme activity

• Inhibitor panels: Use known inhibitors like NSAIDs (diclofenac, sulindac) for rabbit DHRS11 or appropriate inhibitors for human DHRS11 to confirm specificity of observed enzymatic activity

• Cofactor dependency tests: Include experiments with and without NADP+ to verify the cofactor requirement

• Knockout/knockdown validation: Where possible, include DHRS11 knockout or knockdown samples to confirm antibody specificity

• Substrate competition assays: When measuring activity toward a specific substrate, perform competition assays with other steroids to assess catalytic preferences

• pH optimum determination: Establish optimal pH conditions for each substrate, as enzymatic activity can vary significantly with pH for SDR family enzymes

These controls ensure that observed effects are specifically attributable to DHRS11 activity rather than related enzymes or non-specific reactions.

What methodological approaches should be used to differentiate between DHRS11 and other hydroxysteroid dehydrogenases in functional studies?

Differentiating DHRS11 from other hydroxysteroid dehydrogenases requires a multi-faceted approach:

• Selective inhibition profiling:

  • Test with diclofenac and sulindac, which potently inhibit rabbit DHRS11

  • Use comparative inhibition studies with 17β-HSD inhibitors to distinguish activity

• Substrate specificity analysis:

  • DHRS11 catalyzes both 3β-HSD and 17β-HSD activities, while other enzymes may be more specific

  • Measure activity with both types of substrates in parallel

• Recombinant protein studies:

  • Express recombinant DHRS11 alongside other hydroxysteroid dehydrogenases

  • Compare kinetic parameters (Km, Vmax) for various substrates

• Co-immunoprecipitation with activity measurement:

  • Immunoprecipitate DHRS11 using specific antibodies

  • Measure enzyme activity in the immunoprecipitate to confirm it originates from DHRS11

• Mass spectrometry analysis:

  • Identify specific reaction products using LC-MS/MS

  • Compare product profiles between DHRS11 and other hydroxysteroid dehydrogenases

This combined approach allows for reliable differentiation between DHRS11 and other related enzymes in complex biological samples.

How should researchers address potential cross-reactivity issues with DHRS11 antibodies?

To minimize cross-reactivity issues with DHRS11 antibodies:

• Epitope selection and analysis:

  • Choose antibodies targeting unique regions of DHRS11 not conserved in other SDR family members

  • Review the immunogen sequence provided by manufacturers (e.g., amino acids 115-142 or 1-260)

• Pre-absorption controls:

  • Pre-incubate antibody with recombinant DHRS11 protein before application

  • Compare staining patterns between pre-absorbed and non-absorbed antibody

• Orthogonal validation:

  • Correlate antibody staining with mRNA expression data

  • Verify results using multiple antibodies targeting different epitopes

• Cross-species reactivity assessment:

  • Test on tissues from multiple species if cross-species applications are intended

  • Consider the 92% sequence homology between human and rabbit DHRS11 when selecting antibodies

• Knockout/knockdown validation:

  • Use CRISPR-Cas9 or siRNA approaches to generate negative controls

  • Compare staining between wildtype and knockout/knockdown samples

These approaches help ensure that signals detected are specific to DHRS11 rather than related proteins with similar sequences.

What factors should be considered when using DHRS11 antibodies for interaction studies with potential protein partners?

When investigating DHRS11 protein interactions:

• Antibody orientation considerations:

  • Verify that the antibody does not interfere with known or predicted interaction domains

  • Consider using antibodies targeting different epitopes for confirmation

• Co-immunoprecipitation optimization:

  • Test different buffer conditions as interactions may be sensitive to salt concentration

  • Consider mild detergents to preserve protein-protein interactions

  • Validate results with reciprocal co-IP using antibodies against the interaction partner

• Proximity ligation assay (PLA) design:

  • Ensure primary antibodies are raised in different host species

  • Include appropriate positive controls (known interactions) and negative controls

• Structural considerations:

  • The STRING database shows DHRS11 interacts with multiple partners, particularly HSD17B1, HSD17B2, and HSD17B7

  • Consider these known interactions when designing experiments

• Functional validation:

  • Confirm interactions through functional assays measuring enzymatic activity

  • Test how interaction affects substrate specificity or enzyme kinetics

These methodological considerations ensure reliable detection of DHRS11 protein interactions while minimizing artifacts.

How can DHRS11 antibodies be effectively used for studying subcellular localization?

For accurate subcellular localization studies of DHRS11:

• Immunofluorescence optimization:

  • Use fixation methods that preserve subcellular structures (4% paraformaldehyde for most applications)

  • Test permeabilization conditions (0.1-0.5% Triton X-100, digitonin, or saponin) to optimize antibody access

• Confocal microscopy approach:

  • Employ z-stack imaging to fully capture the three-dimensional distribution

  • Use appropriate subcellular markers for co-localization (ER, mitochondria, etc.)

• Subcellular fractionation validation:

  • Complement imaging with biochemical fractionation

  • Use Western blotting of fractions to confirm microscopy observations

• Live-cell imaging considerations:

  • For dynamic studies, consider antibody fragments or nanobodies compatible with live-cell imaging

  • Compare fixed and live-cell results to rule out fixation artifacts

• Super-resolution microscopy applications:

  • For detailed localization, employ super-resolution techniques (STED, PALM, STORM)

  • Ensure antibodies are compatible with super-resolution sample preparation

This comprehensive approach provides reliable information about the subcellular distribution of DHRS11, which may vary by cell type and physiological conditions.

What are the methodological considerations for using DHRS11 antibodies in studying disease-related alterations?

When investigating DHRS11 in disease contexts:

• Tissue microarray analysis:

  • Use standardized antibody dilutions across disease and control tissues

  • Implement quantitative scoring systems for objective comparison

  • Consider multiplexed immunohistochemistry to analyze DHRS11 alongside other markers

• Patient sample considerations:

  • Account for pre-analytical variables (fixation time, processing methods)

  • Include appropriate age and sex-matched controls

  • Consider disease heterogeneity in experimental design

• Expression correlation analysis:

  • Correlate DHRS11 expression with clinical parameters and outcomes

  • Use multivariate analysis to account for confounding factors

• Functional impact assessment:

  • Determine if alterations in DHRS11 expression affect enzyme activity

  • Analyze downstream metabolites in patient samples

• Genetic variation consideration:

  • Investigate if genetic variations in DHRS11 correlate with expression changes

  • Consider how variants might affect antibody binding

These methodological considerations ensure robust and clinically relevant data when studying DHRS11 in disease states.

How should researchers interpret contradictory results when using different DHRS11 antibodies?

When faced with contradictory results using different DHRS11 antibodies:

• Epitope mapping analysis:

  • Compare the immunogen sequences of each antibody

  • Consider whether antibodies recognize different isoforms or post-translational modifications

• Validation hierarchy implementation:

  • Prioritize results from antibodies with the most extensive validation (orthogonal, knockout, etc.)

  • Consider using antibodies validated through the enhanced validation processes

• Isoform-specific considerations:

  • Determine if contradictions reflect isoform-specific detection

  • Verify which isoforms are expressed in your experimental system (isoform 1 is ubiquitous; isoform 3 is tissue-restricted)

• Technical optimization:

  • Test different antigen retrieval methods for IHC applications

  • Optimize blocking conditions to reduce non-specific binding

  • Verify antibody performance in your specific experimental conditions

• Independent methodology confirmation:

  • Use non-antibody methods (mass spectrometry, RNA analysis) to resolve contradictions

  • Employ genetic approaches (CRISPR, RNAi) to validate specificity

This systematic approach helps resolve discrepancies and determines which results are most reliable when using different DHRS11 antibodies.

What are emerging applications of DHRS11 antibodies in cancer research?

DHRS11's role in steroid metabolism suggests potential applications in hormone-dependent cancers:

• Expression correlation studies:

  • Analyze DHRS11 expression across cancer types using tissue microarrays

  • Correlate expression with clinical outcomes and therapy response

• Functional studies in cancer models:

  • Investigate how DHRS11 affects estrogen and androgen metabolism in cancer cells

  • Study the impact of DHRS11 inhibition on cancer cell proliferation

• Biomarker development:

  • Evaluate DHRS11 as a potential diagnostic or prognostic marker

  • Explore its utility in predicting response to hormone therapies

• Therapeutic target assessment:

  • Study DHRS11 inhibition as a potential therapeutic strategy

  • Investigate combination approaches with established hormone therapies

• Cancer metabolism studies:

  • Explore DHRS11's role in cancer-specific metabolic rewiring

  • Investigate its contribution to steroid-dependent signaling pathways

These emerging applications could establish DHRS11 as a significant factor in cancer biology and therapeutic approaches.

How can DHRS11 antibodies be utilized in drug development and toxicology studies?

DHRS11's role in xenobiotic metabolism makes it relevant for drug development and toxicology:

• Drug metabolism studies:

  • Use DHRS11 antibodies to monitor expression in drug metabolism organs

  • Study potential drug-drug interactions involving DHRS11

• Hepatotoxicity assessment:

  • Investigate DHRS11 regulation during drug-induced liver injury

  • Evaluate its role in detoxifying reactive metabolites

• Species differences consideration:

  • Compare DHRS11 expression and activity across species used in toxicology testing

  • Account for the significant functional differences between human and rabbit DHRS11

• Drug candidate screening:

  • Assess candidate compounds for potential interaction with DHRS11

  • Evaluate DHRS11 inhibition or induction by drug candidates

• Precision medicine applications:

  • Study how genetic variations in DHRS11 affect drug metabolism

  • Investigate potential biomarkers for drug response prediction